Professor Michael Barry:

I will be specific about Entresto. It is for heart failure. We started the assessment on 7 March and we finished it on 8 July. That took us four months, which is reasonably quick. That is our component of the delay. It was cost effective and I guess, as Mr. Shaun Flanagan was saying there, having taken everything into account, it was value for money. However, it requires additional expenditure and that is where the affordability issue comes in. The real issue here is that there are 40,000 people with heart failure. Some 20,000 would be eligible and 20,000 would not be. The issue then is to ensure that the appropriate patients get the drug and for it not to seep into the remainder of the 40,000. That is where the budget issue comes around, but it is right-----